Meanwhile, studies did not report a higher risk of adverse events, such as symptomatic thrombosis, deep thrombophlebitis, myocardial infarction, stroke, and hypertension, which were caused by the EPO intervention (21–23). The gene discussed is EPO; the disease is Stroke.